Ambrx partners with BeiGene to Develop Next-Generation Biologics

March, 2019, Ambrx, Inc. and BeiGene, Ltd announced a global research and development collaboration.  BeiGene is a global, commercial-stage, research-based biotechnology company focused on immuno-oncology cancer therapeutics. With a team of over 2,200 employees in...

China implements key regulatory changes to accelerate drug approval

China pharma sector, the second largest in the world, continues to grow rapidly on a CAGR of 10%, which will reach ~$393 Billion in 2025.  Key regulatory changes •   China Joined ICH in 2017: fast drug approval and match the global standards •   NRDL (National...
|JPM Week | Guidebook

|JPM Week | Guidebook

Introduction J.P. Morgan 38th Annual Healthcare Conference (JPM 2020) will take place 13-16 January 2020 in San Francisco, CA, USA. The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry,...
Case Studies: Things you need to know about China partnering

Case Studies: Things you need to know about China partnering

In 2018, Chinese companies made more than 150 cross-border life sciences licensing deals, with the average upfront payment of ~$10 Million, having reached a record high. Over 40% of early- and late-stage assets entered China market through licensing deals.  In this...